65,437 trials
Breast Cancer
Primary: Event-Free Survival (EFS) - Percentage of Participants With an Event — 40.0; 50.9; 42.4 percentage of participants
Rotavirus Infection
Primary: Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the WC3 IgA Assay — 186; 182; 175; 191 participants
Hypophosphatemia, Familial · Hyperparathyroidism
Primary: Area Under the Curve for Parathyroid Hormone (PTHauc) Measurement — 1223; 1449; 987; 1616 nlEq*26hr/ml — p=0.007
Type 2 Diabetes Mellitus
Primary: Cognitive Outcome: Brief Visuospatial Spatial Memory Test -Total Recall (Unit T Score) — 39.46; 41.23; 43.1; 50.9 T-score
HIV · HIV Infections
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 — 85.2; 87.4 percentage of participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26 — -1.30; -0.11 percentage of glycosylated haemoglobin — p=<0.0001
Acquired Immunodeficiency Syndrome · HIV Infections
Primary: Percentage of Participants With Onset of Any Treatment-emergent Grade 3 or 4 Adverse Event Between Baseline and Week 24 — 5.4; 11.1 percentage of participants
Alzheimer´s Disease
Primary: Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog) — 7.4; 8.9; 8.4 Scores on a scale — p=0.476
Parenteral Nutrition-Associated Liver Disease
Primary: The Presence of Cholestasis at Age of 28 Days or When Full Enteral Nutrition is Achieved, Whichever is Longer. — 39; 45 participants who developed Cholestasis
NMDA Receptor Function
Primary: Percent Change in Amelioration of Ketamine-related Task Activation as Measured by Functional Magnetic Resonance Imaging in Inferior Parietal Lobule — -0.17; -0.094…
HIV-1 Infection
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 — 84.0; 89.7 percentage of participants
Cystinosis
Primary: Plasma Pharmacokinetic Parameter: Cmax of Cysteamine — 42.02; 33.06 umol/L
Bladder Cancer
Primary: Percentage of Participants That Respond to Treatment in Arm 1 and Arm 2 — 57.1; 61.4 percentage of participants
Critical Lower Limb Ischemia
Primary: Late Lumen Loss (LLL) of the Target Lesion by Quantitative Vascular Angiography (QVA) — 0.605; 0.616 mm
Brain and Central Nervous System Tumors · Sarcoma
Primary: Number of Patients Who DID NOT Experience Disease Progression or Death by 6 Months After Starting Treatment. — 15 Participants